Osilodrostat improves blood pressure and glycemic control in patients with Cushing's disease: a pooled analysis of LINC 3 and LINC 4 studies.

 0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Richard J Auchus, Marie Bex, Beverly M K Biller, Richard A Feelders, Maria Fleseriu, Mônica R Gadelha, André Lacroix, John Newell-Price, Alberto M Pedroncelli, Andrea Piacentini, Rosario Pivonello, Akira Shimatsu, Przemysław Witek

Ngôn ngữ: eng

Ký hiệu phân loại: 612.14 Blood pressure

Thông tin xuất bản: United States : Pituitary , 2025

Mô tả vật lý:

Bộ sưu tập: NCBI

ID: 751729

 PURPOSE: To evaluate the effect of osilodrostat and hypercortisolism control on blood pressure (BP) and glycemic control in patients with Cushing's disease. METHODS: Pooled analysis of two Phase III osilodrostat studies (LINC 3 and LINC 4), both comprising a 48-week core phase and an optional open-label extension. Changes from baseline in systolic and diastolic BP (SBP and DBP), fasting plasma glucose (FPG), and glycated hemoglobin (HbA RESULTS: Of 210 patients, 82.9% met criteria for hypertension and 40.0% for diabetes at baseline. In patients with hypertension, reductions in mean SBP/DBP were observed from week (W)12 to W72, and 49.1%/58.5% of patients with high SBP/DBP (>
  130/>
 90 mmHg) at baseline had normotensive levels at W72. Antihypertensive medication dose was reduced/stopped in 26.8% of patients, and the proportion taking antihypertensive medication decreased from 54.3% at baseline to 47.3% at W72. In patients with diabetes, mean FPG and HbA CONCLUSIONS: Patients with Cushing's disease and comorbid hypertension/diabetes receiving osilodrostat had rapid and sustained improvements in SBP/DBP and glycemic control, respectively.
Tạo bộ sưu tập với mã QR

THƯ VIỆN - TRƯỜNG ĐẠI HỌC CÔNG NGHỆ TP.HCM

ĐT: (028) 36225755 | Email: tt.thuvien@hutech.edu.vn

Copyright @2024 THƯ VIỆN HUTECH